These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21386934)

  • 81. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
    Greathouse M
    Congest Heart Fail; 2002; 8(6):313-20. PubMed ID: 12461321
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.
    Estacio RO
    Postgrad Med; 2009 May; 121(3):33-44. PubMed ID: 19491538
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.
    Senda A; Mukai Y; Toda T; Hayakawa T; Yamashita M; Eliasson E; Rane A; Inotsume N
    Biol Pharm Bull; 2015; 38(12):1975-9. PubMed ID: 26632190
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K
    Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.
    Omboni S; Volpe M
    Cardiovasc Ther; 2018 Dec; 36(6):e12471. PubMed ID: 30358114
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 93. New insights into the management of hypertension and cardiovascular risk with Angiotensin receptor blockers: observational studies help us?
    Goudev A
    Open Cardiovasc Med J; 2014; 8():35-42. PubMed ID: 24847388
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.
    Lim TM; Ibrahim MI
    Pharm Pract (Granada); 2012 Jul; 10(3):136-42. PubMed ID: 24155829
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.
    Pimenta E; Oparil S
    Integr Blood Press Control; 2010; 3():113-23. PubMed ID: 21949627
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
    Michel MC; Foster C; Brunner HR; Liu L
    Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes.
    Nakamura M; Sasai N; Hisatome I; Ichida K
    Clin Pharmacol; 2014; 6():79-86. PubMed ID: 24833923
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
    Kikuchi K; Tancharoen S; Ito T; Morimoto-Yamashita Y; Miura N; Kawahara K; Maruyama I; Murai Y; Tanaka E
    Int J Mol Sci; 2013 Sep; 14(9):18899-924. PubMed ID: 24065095
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
    Zaiken K; Hudd TR; Cheng JW
    Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.